Schizophrenia Research
Volume 56, Issue 1 , Pages 31-36 , 1 July 2002

Typical antipsychotic drugs — D2 receptor occupancy and depressive symptoms in schizophrenia

  • Rodrigo A Bressan

      Affiliations

    • Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44-2078480807 fax: +44-2078480051
    • ,
  • Durval C Costa

      Affiliations

    • Institute of Nuclear Medicine, University College of London Medical School, Mortimer St, London W1N 8AA, UK
    • ,
  • Hugh M Jones

      Affiliations

    • Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
    • ,
  • Peter J Ell

      Affiliations

    • Institute of Nuclear Medicine, University College of London Medical School, Mortimer St, London W1N 8AA, UK
    • ,
  • Lyn S Pilowsky

      Affiliations

    • Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
    • Institute of Nuclear Medicine, University College of London Medical School, Mortimer St, London W1N 8AA, UK

Received 29 October 2000 ,Accepted 1 February 2001.

References 

  1. Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr. Res. 1992;6:201–208
  2. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders — DSM VI. Washington, DC: American Psychiatric Press; 1994;
  3. Ananth J, Ghadirian AM. Drug-induced mood disorders. Int. Pharmacopsychiatry. 1980;15:59–73
  4. Bressan RA, Costa DC, Jones HM, Ell RW, Pilowsky LS. High striatal dopamine D2/D3 blockade does not induce depression in schizophrenia—a prospective study. J. Psychopharmacology. 1999;13(3):A17
  5. Bressan RA, Chaves AC, Shirakawa I, Mari JJ. Validity study of the Brazilian version of the Calgary Depression Scale for schizophrenia. Schizophr. Res. 1998;32:41–49
  6. Bruke T, Podreka I, Algelbrger P, Wenger S, Topitz A, Kufferle B. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J. Cer. Blood Flow Metabol. 1991;11:220–228
  7. Costa DC, Verhoeff NP, Cullum ID, Ell PJ, Syed GM. In vivo characterisation of 3-iodo-6-methoxybenzamide [123I] in humans. Eur. J. Nucl. Med. 1990;16:813–816
  8. De Haan L, Lavalaye J, Linzen D, Dingemans P, Booji J. Subjective experience and striatal dopamine D2 receptor occupancy in patients with recent-onset schizophrenia treated with olanzapine or risperidone. Am. J. Psychiatry. 2000;157:1019–1020
  9. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry. 1976;33:766–771
  10. Galdi J. The causality of depression in schizophrenia. Br. J. Psychiatry. 1983;142:621–624
  11. Harrow M, Yonan CA, Sands JR, Marengo J. Depression in schizophrenia, are neuroleptics, akinesia or anhedonia involved?. Schizophr. Bull. 1994;20:327–338
  12. Helmchen H, Hippius H. Depression syndrome in the course of neuroleptic therapy. Nervenarzt. 1967;38:455–458
  13. Kapur S, Mann JJ. Role of the dopaminergic system in depression. Biol. Psychiatry. 1992;32:1–17
  14. Kapur S, Zipursky RB, Jones C, Remington GJ, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry. 2000;157:514–520
  15. Overall J, Gorham D. The brief psychiatric rating scale. Psychol. Rep. 1962;10:799–812
  16. Perkins DO. Adherence to antipsychotic medications. J. Clin. Psychiatry. 1999;60(21):25–30
  17. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NPLG, Kerwin RW. Antipsychotic medication, D2 dopamine receptor blockade and clinical response — a [123I]-IBZM SPET study. Psychol. Med. 1993;23(3):791–797
  18. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NPLG, Kerwin RW. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients — a [123I]-IBZM single photon emission computerised tomography study. Br J Psychiatry. 1994;164:16–26
  19. Siris SG. Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr. Bull. 1991;17:75–98
  20. Siris SG. Depression in schizophrenia: perspectives in the era of atypical antipsychotic agents. Am. J. Psychiatry. 2000;157:1379–1389
  21. Tollefson GD, Sanger TM, Beasley CM, Tran PV. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol. Psychiatry. 1998;43:803–810
  22. Van Putten T, May PRA. “Akinetic depression“ in schizophrenia. Arch. Gen. Psychiatry. 1978;43:1015–1016
  23. Ventura J, Green MF, Shaner A, Liberman RP. Training and quality assurance with the Brief Psychiatric Rating Scale. J. Meth. Psychiatric Res. 1993;3:221–244
  24. White L, Harvey PD, Opler L, Lindenmayer JP, PANSS Study Group . Empirical assessment of the clinical symptoms in schizophrenia. Psychopathology. 1997;30:263–274

☆ Oral presentation at the Society of Biological Psychiatry 55th Annual Convention, Chicago, Illinois, May 11–13, 2000 (Biol Psychiatry 2000; 47(8):128S). A Letter to the Editor of the American Journal of Psychiatry commenting a paper (De Haan et al., 2000) is in press.

PII: S0920-9964(01)00185-2

doi: 10.1016/S0920-9964(01)00185-2

Schizophrenia Research
Volume 56, Issue 1 , Pages 31-36 , 1 July 2002

Article Tools

* Image Usage & Resolution